These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17253434)

  • 1. [The level of cotinine - marker of tobacco smoking, in patients with hyperthyroidism].
    Czarnywojtek A; Zgorzalewicz-Stachowiak M; Florek E; Piekoszewski W; Warmuz-Stangierska I; Kulińska-Niedziela I; Komar-Rychlicka K; Sowiński J
    Endokrynol Pol; 2006; 57(6):612-8. PubMed ID: 17253434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of radioiodine therapy on ocular changes and their relation to urine cotinine level in patients with Graves' Ophthalmopathy.
    Czarnywojtek A; Zgorzalewicz-Stachowiak M; Budny B; Wasko R; Florek E; Szczepanek E; Komar-Rychlicka K; Waligorska-Stachura J; Kurdybacha P; Miechowicz I; Ruchala M
    Neuro Endocrinol Lett; 2013; 34(3):241-8. PubMed ID: 23685424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients.
    Sieminska L; Niedziolka D; Pillich A; Kos-Kudla B; Marek B; Nowak M; Borgiel-Marek H
    J Endocrinol Invest; 2008 Sep; 31(9):745-9. PubMed ID: 18997483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.
    Träisk F; Tallstedt L; Abraham-Nordling M; Andersson T; Berg G; Calissendorff J; Hallengren B; Hedner P; Lantz M; Nyström E; Ponjavic V; Taube A; Törring O; Wallin G; Asman P; Lundell G;
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3700-7. PubMed ID: 19723755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Urinary cotinine in patients with hyperthyroidism].
    Czarnywojtek A; Rabska-Pietrzak B; Ruchała M; Florek E; Piekoszewski W; Warmuz-Stangierska I; Michałek K; Sowiński J
    Przegl Lek; 2005; 62(10):1010-2. PubMed ID: 16521942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
    Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy.
    Subekti I; Boedisantoso A; Moeloek ND; Waspadji S; Mansyur M
    Acta Med Indones; 2012 Apr; 44(2):114-21. PubMed ID: 22745141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
    Nicolì F; Lanzolla G; Mantuano M; Ionni I; Mazzi B; Leo M; Sframeli A; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
    J Endocrinol Invest; 2021 Mar; 44(3):581-585. PubMed ID: 32648002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pro 12 Ala PPAR gamma gene polymorphism: possible modifier of the activity and severity of thyroid-associated orbitopathy (TAO).
    Alevizaki M; Mantzou E; Cimponeriu A; Saltiki K; Philippou G; Wiersinga W
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):464-8. PubMed ID: 18624999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Determination of 4-(methylnirosamino) -4-(3-pyridyl)-1-butanol (NNA) in urine of pregnant women by means of LC/MS/MS].
    Florek E; Piekoszewski W; Lechowicz W; Szymańska A; Kornacka MK
    Przegl Lek; 2006; 63(10):926-31. PubMed ID: 17288186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe unilateral orbitopathy in a patient with Hashimoto's thyroiditis - a case report.
    Cyranska-Chyrek E; Olejarz M; Szczepanek-Parulska E; Stajgis P; Pioch A; Ruchala M
    BMC Ophthalmol; 2019 Jan; 19(1):9. PubMed ID: 30621642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for Graves' Orbitopathy in surgical patients-Results of a 10-year retrospective study with review of the literature.
    Tabriz N; Gruben A; Uslar V; Weyhe D
    Endocrinol Diabetes Metab; 2021 Jan; 4(1):e00210. PubMed ID: 33532627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients.
    Mukasa K; Yoshimura Noh J; Kouzaki A; Ohye H; Kunii Y; Watanabe N; Yoshihara A; Matsumoto M; Suzuki M; Ito K
    Endocr J; 2016; 63(2):151-7. PubMed ID: 26581710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence, risk factors, and clinical features of thyroid-associated ophthalmopathy in multiethnic Malaysian patients with Graves' disease.
    Lim SL; Lim AK; Mumtaz M; Hussein E; Wan Bebakar WM; Khir AS
    Thyroid; 2008 Dec; 18(12):1297-301. PubMed ID: 19012471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe thyroid-associated orbitopathy in Hashimoto's thyroiditis. Report of 2 cases.
    Yoshihara A; Yoshimura Noh J; Nakachi A; Ohye H; Sato S; Sekiya K; Kosuga Y; Suzuki M; Matsumoto M; Kunii Y; Watanabe N; Mukasa K; Inoue Y; Ito K; Ito K
    Endocr J; 2011; 58(5):343-8. PubMed ID: 21427503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of immunosuppressive treatment of Graves' orbitopathy is not affected by previous anti-thyroid drugs or by radioiodine therapy of Graves' disease.
    Jagiełło-Korzeniowska A; Sokołowski A; Krzentowska-Korek A; Miklaszewska G; Bałdys-Waligórska A
    Endokrynol Pol; 2016; 67(6):554-561. PubMed ID: 28042648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.